BSX Boston Scientific

8-K Current Report

Filed: February 26, 2026

Health Care

Surgical & Medical Instruments & Apparatus

Boston Scientific (BSX) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
3 items

Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• BSX arranged $11B total acquisition financing: $3B 5-year revolver (matures 2031), $2B 364-day revolver, and $6B 364-day delayed-draw term loan
• All three facilities tied to Penumbra (PEN) acquisition announced Jan 14, 2026; term loan tranches ($1B + $5B) drawable only at deal closing

+3 more insights

Item 1.02 · Termination of a Material Definitive Agreement

• Terminated 2021 Revolving Credit Agreement (Wells Fargo as agent) on Feb 26, 2026, replaced by new 2026 facility
• Prior agreement had been amended 3 times since May 2021 inception, signaling active liability management

+1 more insights

Item 2.03 · Creation of a Direct Financial Obligation

• BSX entered into 2026 Credit Agreements — full terms/details referenced from a prior section of the same filing
• Item 2.03 flags a material new financial obligation, indicating new debt or credit facility commitments by BSX

+1 more insights

Other Boston Scientific 8-K Filings

8-K Feb 23, 2026

Get deeper insights on Boston Scientific

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.